← Eichor
Condition: Fabry Disease Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Fabry Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeedin
Phase N/A · 1 location(s) · Amicus Therapeutics · NCT04252066Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI
NA · 1 location(s) · University Health Network, Toronto · NCT04856059Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting
Phase N/A · 7 location(s) · Chiesi Italia · NCT07109375Molecular Imaging in Fabry Disease of the Heart
Phase N/A · 1 location(s) · University of Cambridge · NCT06226987Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
Phase 2/Phase 3 · 10 location(s) · Chiesi Farmaceutici S.p.A. · NCT05710692Evaluation of HEArt invoLvement in Patients With FABRY Disease
Phase N/A · 1 location(s) · Wuerzburg University Hospital · NCT03362164Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal
Phase N/A · 2 location(s) · University of Minnesota · NCT01581424Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT07382128Fabry Disease Registry & Pregnancy Sub-registry
Phase N/A · 284 location(s) · Genzyme, a Sanofi Company · NCT00196742Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR Study
Phase N/A · 1 location(s) · Yonsei University · NCT07235709the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease
Phase N/A · 1 location(s) · Caroline Michaela Kistorp · NCT06776419Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation
Phase N/A · 3 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06813443Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease
NA · 2 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT06539624Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
Phase 1/Phase 2 · 8 location(s) · UniQure Biopharma B.V. · NCT06270316A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
Phase N/A · 10 location(s) · Chiesi Farmaceutici S.p.A. · NCT06663358A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
Phase 1/Phase 2 · 10 location(s) · GC Biopharma Corp · NCT06858397Functional Capacity in Anderson-Fabry Disease Patients
Phase N/A · 5 location(s) · IRCCS Policlinico S. Donato · NCT06884358Characterizing the Retinal Microvasculature in Patients with Fabry Disease: a Prospective Observational Study
Phase N/A · 1 location(s) · Technical University of Munich · NCT06758648Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Technique
Phase N/A · 1 location(s) · Chinese Academy of Medical Sciences, Fuwai Hospital · NCT07336394Italian Anderson Fabry Disease Cardiovascular Registry
Phase N/A · 54 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06806813Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women
Phase N/A · 5 location(s) · Chiesi Farmaceutici S.p.A. · NCT06941025Taiwan Associated Genetic and Nongenetic Small Vessel Disease
Phase N/A · 1 location(s) · National Taiwan University Hospital · NCT05473637Evaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry Disease
EARLY_Phase 1 · 1 location(s) · Children's Hospital of Fudan University · NCT06207552Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
Phase N/A · 1 location(s) · Mackay Memorial Hospital · NCT05698901RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseas
Phase N/A · 17 location(s) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · NCT06935578Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients wit
Phase N/A · 1 location(s) · Scientific Institute San Raffaele · NCT06607471A Study of Replagal in Children and Adults With Fabry Disease in India
Phase 4 · 3 location(s) · Shire · NCT05067868National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852CVI Alterations in FD: a Prospective, Multicenter, Observational Cohort Study
Phase N/A · 1 location(s) · China National Center for Cardiovascular Diseases · NCT06512571Canadian Fabry Disease Initiative (CFDI) National Registry
Phase N/A · 5 location(s) · Canadian Fabry Research Consortium · NCT00455104
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.